Infertility, Female, Infertility, Male
Conditions
Keywords
Blastocyst Rate, IVF, Embryo Culture, Antioxidants
Brief summary
The goal of this clinical trial is to investigate the impact of repeated antioxidant supplementation on blastocyst utilization and expansion rates in embryos under different oxygen concentrations. The study aims to answer the following main questions: * Does adding antioxidants every 12 hours to embryo culture media improve usable and expanded blastocyst utilization rates on days 5 and 6? * How are the O2 concentrations related to the effect of different methods of antioxidants supplementation on blastocysts utilization and expansion rates? Participants in this study are infertile couples undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles. * Zygotes will be incubated at either 5% or 20% oxygen tension until the blastocyst stage. * Sibling zygotes will be divided into four groups: Group 1A and 1B: Antioxidants every 12 hours at either 5% or 20% O2 tension, respectively. Group 2A and 2B: Antioxidants only once at the beginning of embryo culture at either 5% or 20% O2 tension, respectively. Researchers will compare the four groups to determine if the repeated antioxidant supplementation of the culture media leads to improved blastocyst utilization and expansion rates compared to the baseline group.
Detailed description
This study is focused on the role of antioxidants (AOXs) in mitigating reactive oxygen species and oxidative stress, which have been associated with failure in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). The research aimed to evaluate the effect of two different methods of antioxidants supplementation at two O2 tensions on blastocyst utilization and expansion rates. To achieve this, 3603 zygotes from infertile couples undergoing IVF or ICSI were included in the study. The zygotes were divided into two groups: Group 1A and 1B: Antioxidants every 12 hours at either 5% or 20% O2 tension, respectively. Group 2A and 2B: Antioxidants only once at the beginning of embryo culture at either 5% or 20% O2 tension, respectively. .
Interventions
DRUGEmbryORP®
EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
DEVICEO2 tension 20%
After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2, and 95%
DEVICEO2 tension 5%
After fertilization check, zygotes were placed in the incubator at 37°C, 8% CO2 and 95%
Sponsors
Liliana Berenice Ramírez Domínguez
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Intervention model description
The data registry utilized internal and external measures to ensure accuracy. SOPs were developed for registry operations and data analysis. Data were recorded in clinical records and clinic-specific databases. Regular backups and monthly audits were conducted to safeguard data and verify accuracy. External audits occurred every 6 months. Access controls protected privacy. Appropriate statistical techniques and sample size assessment were used for data analysis. A study on embryo development analyzed 3603 zygotes, assessing blastocyst outcomes and detailing procedures for ovarian stimulation, retrieval, sperm preparation, and assisted reproduction techniques. These measures ensured accurate and reliable results.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 37 Years
Healthy volunteers
No
Inclusion criteria
* Infertile women with from 18 to 37 years old at the moment of oocyte collection, tubal factor, polycystic ovary syndrome, uterine factor, or unexplained infertility. * More than 2 oocytes by conventional in vitro fertilization (cIVF) and intracytoplasmic sperm injection (ICSI).
Exclusion criteria
* Infertile woman in assisted reproduction treatment with less than 2 oocytes collected. * Infertile woman in assisted reproduction treatment with less than 2 oocytes fertilized by conventional in vitro fertilization (cIVF) and intracytoplasmic sperm injection (ICSI)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of usable blastocysts on day 5 | 5 days | Usable blastocysts were defined as vitrified, transferred, and/or biopsied blastocysts at day 5 |
| Rate of expanded blastocysts on day 5 | 5 days | Expanded blastocysts were defined as usable blastocysts with a 4 to 6 expansion grade at day 5 |
| Rate of sable blastocysts on day 6 | 6 days | Usable blastocysts were defined as vitrified, transferred, and/or biopsied blastocysts at day 6 |
| Rate of expanded blastocysts on day 6 | 6 days | Expanded blastocysts were defined as usable blastocysts with a 4 to 6 expansion grade at day 6 |
| Rate of acumulative usable blastocysts | 5 - 6 days | Usable blastocysts were defined as vitrified, transferred, and/or biopsied blastocysts at days 5 and 6 |
| Rate of acumulative expanded blastocysts. | 5 - 6 days | Expanded blastocysts were defined as usable blastocysts with a 4 to 6 expansion grade at days 5 and 6 |
Countries
Mexico
Outcome results
None listed